SrasV1, PascalFrancis, Checkpoint, bibRecord, 000301

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Identifieur interne : 000301 ( PascalFrancis/Checkpoint ); précédent : 000300; suivant : 000302

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Auteurs : Kai Schulze [Allemagne] ; Caroline Staib [Allemagne] ; Hermann M. Sch Tzl [Allemagne] ; Thomas Ebensen [Allemagne] ; Volker Erfle [Allemagne] ; Carlos A. Guzman [Allemagne]

Source :

Vaccine [ 0264-410X ] ; 2008.

RBID : Pascal:09-0039741

Descripteurs français

Pascal (Inist)
- Virus syndrome respiratoire aigu sévère, Virus vaccine, Vaccination, Réponse immune, Nucléocapside, Protéine, Adjuvant immunologique, Muqueuse, Immunisation, Vaccin.
Wicri :
- topic : Vaccination, Vaccin.

English descriptors

KwdEn :
- Immune response, Immunization, Immunological adjuvant, Mucosa, Nucleocapsid, Protein, Severe acute respiratory syndrome virus, Vaccination, Vaccine, Vaccinia virus.

Abstract

Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.

Affiliations:

Allemagne

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000239
to stream PascalFrancis, to step Curation: 000749

Links to Exploration step

Pascal:09-0039741

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</title>
<author><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0039741</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 09-0039741 INIST</idno>
<idno type="RBID">Pascal:09-0039741</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000239</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000749</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000301</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000301</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</title>
<author><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Immune response</term>
<term>Immunization</term>
<term>Immunological adjuvant</term>
<term>Mucosa</term>
<term>Nucleocapsid</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccinia virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Virus vaccine</term>
<term>Vaccination</term>
<term>Réponse immune</term>
<term>Nucléocapside</term>
<term>Protéine</term>
<term>Adjuvant immunologique</term>
<term>Muqueuse</term>
<term>Immunisation</term>
<term>Vaccin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccination</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>51</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHULZE (Kai)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STAIB (Caroline)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SCHÄTZL (Hermann M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>EBENSEN (Thomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ERFLE (Volker)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GUZMAN (Carlos A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>6678-6684</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000196098830250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0039741</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus vaccine</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccinia virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vaccinia virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Réponse immune</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Immune response</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Respuesta inmune</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Nucléocapside</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nucleocapsid</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Nucleocápside</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Protéine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Protein</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Proteína</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Adjuvant immunologique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Immunological adjuvant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Muqueuse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Mucosa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Mucosa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Immunisation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunization</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inmunización</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Orthopoxvirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Orthopoxvirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Orthopoxvirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Chordopoxvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Chordopoxvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Chordopoxvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poxviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Poxviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Poxviridae</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>026</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name>
</noRegion>
<name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name>
<name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name>
<name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
<name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000301 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000301 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:09-0039741
   |texte=   A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri